DCC

Content

D18A0005

High Expansion CAR-T Process

Project Description
Chimeric antigen receptor (CAR)-T cell therapy is a break through strategy to treat cancer patients.  However, large amount of CAR-T cells would be required for the animal experiments and clinical trials.  This process can expand the CAR-T cells to 30-100 fold of initial cell number in the serum-free condition within 2 weeks.  In addition, the major populations of CAR-T cells prepared in the process were early differentiated Th1 and CTLs, potentially beneficial to therapeutic potency.  In summary, this process could prepare more than 108 CAR-T cells from about 106 CAR-T cells to be able to reduce the cost of goods and loading of patients, and the early differentiated T cell subsets might be able to increase the therapeutic potency of CAR-T cells.


 
※欲下載完整檔案請 登入/會員註冊